Patents by Inventor Qun Sun

Qun Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11510895
    Abstract: This document relates to non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising non-covalently bound complexes comprising cabazitaxel and human serum albumin. This document also relates to compositions comprising cabazitaxel and human serum albumin. This document also relates to compositions consisting essentially of cabazitaxel and human serum albumin.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 29, 2022
    Assignee: Zhuhai Beihai Biotech Co., Ltd.
    Inventor: Qun Sun
  • Publication number: 20220370399
    Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.
    Type: Application
    Filed: July 18, 2022
    Publication date: November 24, 2022
    Inventor: Qun Sun
  • Publication number: 20220370569
    Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.
    Type: Application
    Filed: August 5, 2022
    Publication date: November 24, 2022
    Inventor: Qun Sun
  • Publication number: 20220361551
    Abstract: A fully automatic peanuts peeling robot for seeds retention and a method using the same are provided. The robot includes a processing mechanism, a feeding mechanism and a screening mechanism. The processing mechanism includes an aluminum profile support bracket, a bracket assembly, a conveyor belt device, and a conversion device, a sensor device and a cut-off device; the aluminum profile support bracket is fixedly connected to the bracket assembly; the bracket assembly includes a first bracket assembly, a second bracket assembly, and a third bracket assembly; and the aluminum profile support bracket is fixedly connected to the conveyor belt device; the conveyor belt device includes a first conveyor belt assembly, a second conveyor belt assembly, and a third conveyor belt assembly; the conveyor belt device is fixedly connected to the conversion device.
    Type: Application
    Filed: April 14, 2021
    Publication date: November 17, 2022
    Applicant: Liaocheng University
    Inventors: Qun Sun, Fuguo Ren, Ying Zhao, Dongjie Zhao
  • Publication number: 20220362205
    Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.
    Type: Application
    Filed: July 26, 2022
    Publication date: November 17, 2022
    Inventor: Qun Sun
  • Patent number: 11475879
    Abstract: Text content is determined. The text content is input to a content classifying model. The content classifying model is adapted to determine a probability of the text content belonging to a category. An evaluated value of quality of the text content is determined according to the probability of the category and a weight of the category. The weight represents importance of the category.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: October 18, 2022
    Assignee: Beijing Xiaomi Pinecone Electronics Co., Ltd.
    Inventors: Xiao Lu, Qun Guo, Erli Meng, Bin Wang, Hongxu Ji, Lei Sun
  • Patent number: 11459321
    Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-spectrum viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 4, 2022
    Assignee: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Lillian W. Chiang, Eain Anthony Murphy, Qun Sun, Frank Kayser, Sarah Jocelyn Fink
  • Publication number: 20220278860
    Abstract: A system, a method and a device for developing a smart contract are provided. A particular embodiment of the system comprises a specification acquisition module configured to acquire specification of a target smart contract interface, a client development module configured to generate, on the basis of the specification of the target smart contract interface, a smart contract client side interface and a smart contract client side agent, the smart contract client side interface and the smart contract client side agent being used to construct a client smart contract application, and a server development module configured to generate, on the basis of the interface specification of the target smart contract, a smart contract server interface and a smart contract server skeleton, the smart contract server interface and the smart contract server skeleton being used to construct a server smart contract.
    Type: Application
    Filed: April 1, 2020
    Publication date: September 1, 2022
    Applicant: Jingdong Technology Information Technology Co., Ltd.
    Inventors: Chao Ma, Ming Zhao, Chunwei Liu, Yi Wang, Qun Lin, Haibo Sun
  • Patent number: 11419842
    Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 23, 2022
    Assignee: Zhuhai Beihai Biotech Co., Ltd.
    Inventor: Qun Sun
  • Patent number: 11413265
    Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: August 16, 2022
    Assignee: Zhuhai Beihai Biotech Co., Ltd.
    Inventor: Qun Sun
  • Publication number: 20220226444
    Abstract: This document relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, and human serum albumin, wherein the fosaprepitant, or a pharmaceutically acceptable salt thereof, and the human serum albumin in the composition have a ratio by weight from about 1:0.1 to about 1:500. This document also relates to a composition comprising aprepitant and human serum albumin, wherein the aprepitant and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:1000. This document also relates to a composition comprising fosaprepitant, or a pharmaceutically acceptable salt thereof, aprepitant and human serum albumin.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 21, 2022
    Inventor: Qun Sun
  • Patent number: 11374404
    Abstract: Disclosed is a low-voltage DC power distribution fast switching device. The device includes a positive output terminal electrically connected to a positive pole of a load, and no less than two switching circuits connected in parallel with each other; the switching circuit includes a positive input terminal electrically connected to a positive pole of common negative power supplies, a supplementary diode cluster composed of no less than one diode connected in series, and a thyristor connected between the positive input terminal and the positive output terminal; the positive input terminal is electrically connected to an anode of the supplementary diode cluster and an anode of the thyristor, and the positive output terminal is electrically connected to a cathode of the complementary diode cluster and a cathode of the thyristor.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: June 28, 2022
    Assignees: State Grid Jiangsu Electric Power Co., Ltd. Research Institute, State Grid Corporation of China, State Grid Jiangsu Electric Power Co., Ltd., Jiangsu Electric Power Research Institute Co., Ltd.
    Inventors: Yubo Yuan, Tiankui Sun, Jinggang Yang, Xiaodong Yuan, Lei Gao, Mingming Shi, Peng Li, Wei Su, Kun Yang, Xinyao Si, Jianhua Qin, Xin Fang, Xiaolong Xiao, Ruihuang Liu, Chenqing Wang, Jiahao Guo, Yunlong Jiang, Shuyi Zhuang, Qun Li, Jian Liu, Shu Chen
  • Patent number: 11358961
    Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.
    Type: Grant
    Filed: December 22, 2019
    Date of Patent: June 14, 2022
    Assignee: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
  • Publication number: 20220135556
    Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Applicant: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
  • Publication number: 20210386741
    Abstract: This document relates to compositions comprising a non-covalently bound complex comprising ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of ibrutinib and human serum albumin, wherein the ibrutinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 16, 2021
    Inventor: Qun Sun
  • Publication number: 20210139475
    Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-specturm viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.
    Type: Application
    Filed: October 17, 2018
    Publication date: May 13, 2021
    Applicant: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Lillian W. Chiang, Eain Anthony Murphy, Qun Sun, Frank Kayser, Sarah Jocelyn Fink
  • Patent number: 10980792
    Abstract: This document relates to compositions comprising a non-covalently bound complex comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 20, 2021
    Inventor: Qun Sun
  • Publication number: 20210052540
    Abstract: This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.
    Type: Application
    Filed: April 19, 2019
    Publication date: February 25, 2021
    Inventor: Qun Sun
  • Publication number: 20210040049
    Abstract: This document relates to compounds useful as agents for preventing or treating human cytomegalovirus (HCMV) infections.
    Type: Application
    Filed: June 21, 2020
    Publication date: February 11, 2021
    Applicant: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
  • Publication number: 20210023041
    Abstract: This document relates to a composition comprising Docetaxel, human serum albumin, and one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1. This document also relates to a composition comprising Docetaxel, human serum albumin, one or more amino acids selected from aspartic acid, glutamic acid, and cysteine, and a sugar alcohol or a sugar, wherein the human serum albumin and the Docetaxel in the composition have a ratio by weight of no less than 60:1.
    Type: Application
    Filed: April 11, 2019
    Publication date: January 28, 2021
    Inventor: Qun Sun